{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T23:05:50Z","timestamp":1767135950478,"version":"build-2238731810"},"update-to":[{"DOI":"10.1002\/14651858.cd011810","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2017,4,7]],"date-time":"2017-04-07T00:00:00Z","timestamp":1491523200000}}],"reference-count":57,"publisher":"Wiley","issue":"4","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd011810.pub2","type":"journal-article","created":{"date-parts":[[2017,4,7]],"date-time":"2017-04-07T10:25:25Z","timestamp":1491560725000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Chlorpromazine versus clotiapine for schizophrenia"],"prefix":"10.1002","volume":"2017","author":[{"given":"Shahrzad","family":"Mazhari","sequence":"first","affiliation":[{"name":"Kerman University of Medical Sciences; Neuroscience Research Center, Institute of Neuropharmacology; Kerman Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saeed","family":"Esmailian","sequence":"additional","affiliation":[{"name":"Kerman University of Medical Sciences; Department of Medicine; Jahad Blvd Ebn Sina Avenue Kerman Iran 7619813159"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armita","family":"Shah-Esmaeili","sequence":"additional","affiliation":[{"name":"Kerman University of Medical Sciences; Research Center for Modeling in Health, Institute for Futures Studies in Health; Haft Bagh Avenue Block C Kerman Iran 7616911317"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali S","family":"Goughari","sequence":"additional","affiliation":[{"name":"Kerman University of Medical Sciences; Department of Medicine; Jahad Blvd Ebn Sina Avenue Kerman Iran 7619813159"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azam","family":"Bazrafshan","sequence":"additional","affiliation":[{"name":"Kerman University of Medical Sciences; Neuroscience Research Center, Institute of Neuropharmacology; Kerman Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morteza","family":"Zare","sequence":"additional","affiliation":[{"name":"Shiraz University of Medical Sciences; Nutrition Research Center, School of Nutrition and Food Sciences; Shiraz Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,4,7]]},"reference":[{"key":"10.1002\/14651858.CD011810.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1600-0447.1974.tb08894.x","article-title":"A controlled trial of clotiapine and chlorpromazine in acute schizophrenic syndromes","volume":"Suppl. 255","author":"Jacobsson","year":"1974","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"9","key":"10.1002\/14651858.CD011810.pub2-BIB0002|cit2","first-page":"721","article-title":"A double-blind, controlled study of the effects of clotiapine and chlorpromazine on schizophrenia","volume":"11","author":"Kaneko","year":"1969","journal-title":"Clinical Psychiatry"},{"key":"10.1002\/14651858.CD011810.pub2-BIB0003|cit3","unstructured":"Belmaker R Clotiapine for schizophrenia Stanley Foundation Research Programs 2006"},{"key":"10.1002\/14651858.CD011810.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.schres.2005.07.007","article-title":"Clotiapine compared with chlorpromazine in chronic schizophrenia","volume":"80","author":"Geller","year":"2005","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD011810.pub2-BIB0005|cit5","unstructured":"Schliefer T Bersudsky Y Geller V Belmaker RH Clotiapine in schizophrenia: a controlled study 16th European College of Neuropsychopharmacology Congress Prague, Czech Republic 2003"},{"key":"10.1002\/14651858.CD011810.pub2-BIB0006|cit6","first-page":"945","article-title":"Chlorpromazine, clotiapine and thioridaz - a comparative clinical trial on Bantu psychotic patients","volume":"45","author":"Wyk","year":"1971","journal-title":"South African Medical Journal"},{"key":"10.1002\/14651858.CD011810.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1741-7015-3-15","article-title":"Chlorpromazine for schizophrenia: a Cochrane systematic review of 50 years of randomised controlled trials","volume":"3","author":"Adams","year":"2005","journal-title":"BMC Medicine"},{"issue":"1","key":"10.1002\/14651858.CD011810.pub2-BIB0008|cit8","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000284.pub3","article-title":"Chlorpromazine versus placebo for schizophrenia","author":"Adams","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"12","key":"10.1002\/14651858.CD011810.pub2-BIB0009|cit9","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007445.pub2","article-title":"Chlorpromazine for psychosis induced aggression or agitation","author":"Ahmed","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD011810.pub2-BIB0010|cit10","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006329","article-title":"Cessation of medication for people with schizophrenia already stable on chlorpromazine","author":"Almerie","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7066","key":"10.1002\/14651858.CD011810.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD011810.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.bbr.2014.07.025","article-title":"Serotonin in antipsychotic drugs action","volume":"277","author":"Amato","year":"2015","journal-title":"Behavioural Brain Research"},{"issue":"4","key":"10.1002\/14651858.CD011810.pub2-BIB0013|cit13","first-page":"495","article-title":"Fifty years chlorpromazine: a historical perspective","volume":"3","author":"Ban","year":"2007","journal-title":"Neuropsychiatric Disease and Treatment"},{"issue":"4","key":"10.1002\/14651858.CD011810.pub2-BIB0014|cit14","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011662","article-title":"Acetophenazine versus chlorpromazine for schizophrenia","author":"Bazrafshan","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD011810.pub2-BIB0015|cit15","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002304.pub2","article-title":"Clotiapine for acute psychotic illnesses","author":"Berk","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011810.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.315.7108.600","article-title":"Statistics notes. Trials randomised in clusters","volume":"315","author":"Bland","year":"1997","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD011810.pub2-BIB0017|cit17","first-page":"405","article-title":"The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use","volume":"54","author":"Boissel","year":"1999","journal-title":"Therapie"},{"key":"10.1002\/14651858.CD011810.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1136\/bmj.316.7126.221","article-title":"Meta-analysis: unresolved issues and future developments","volume":"16","author":"Davey Smith","year":"1998","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD011810.pub2-BIB0019|cit19","unstructured":"Deeks J Issues in the selection for meta-analyses of binary data 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town Cape Town The Cochrane Collaboration 2000"},{"key":"10.1002\/14651858.CD011810.pub2-BIB0020|cit20","unstructured":"Deeks JJ Higgins JPT Altman DG (editors) Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"6","key":"10.1002\/14651858.CD011810.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' patient care behavior","volume":"7","author":"Divine","year":"1992","journal-title":"Journal of General Internal Medicine"},{"key":"10.1002\/14651858.CD011810.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1002\/sim.1301","article-title":"Issues in the meta-analysis of cluster randomized trials","volume":"21","author":"Donner","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD011810.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD011810.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"6","key":"10.1002\/14651858.CD011810.pub2-BIB0025|cit25","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011709","article-title":"Chlorpromazine versus piperacetazine for schizophrenia","author":"Eslami Shahrbabaki","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD011810.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"issue":"2-3","key":"10.1002\/14651858.CD011810.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.schres.2005.07.007","article-title":"Clotiapine compared with chlorpromazine in chronic schizophrenia","volume":"80","author":"Geller","year":"2005","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD011810.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/oxfordjournals.aje.a009904","article-title":"Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994","volume":"149","author":"Gulliford","year":"1999","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD011810.pub2-BIB0029|cit29","volume-title":"Methodology in Evaluation of Psychiatric Treatment","author":"Helgason","year":"1983"},{"key":"10.1002\/14651858.CD011810.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD011810.pub2-BIB0031|cit31","unstructured":"Higgins JPT Green S (editors) Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD011810.pub2-BIB0032|cit32","unstructured":"Higgins JPT Altman DG Sterne JAC (editors) Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD011810.pub2-BIB0033|cit33","unstructured":"Higgins JPT Deeks JJ Altman DG (editors) Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"1","key":"10.1002\/14651858.CD011810.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1365-2141.2009.07707.x","article-title":"Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials","volume":"146","author":"Hutton","year":"2009","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD011810.pub2-BIB0035|cit35","volume-title":"Positive and Negative Syndrome Scale (PANSS) Manual","author":"Kay","year":"1986"},{"issue":"2","key":"10.1002\/14651858.CD011810.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The Positive and Negative Syndrome Scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophrenia Bulletin"},{"issue":"8","key":"10.1002\/14651858.CD011810.pub2-BIB0037|cit37","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011831","article-title":"Chlorpromazine versus penfluridol for schizophrenia","author":"Khalili","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD011810.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.biopsych.2005.10.020","article-title":"Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology","volume":"59","author":"Leon","year":"2006","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD011810.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.187.4.366","article-title":"Clinical implications of brief psychiatric rating scale scores","volume":"187","author":"Leucht","year":"2005","journal-title":"British Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD011810.pub2-BIB0040|cit40","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004278.pub2","article-title":"Haloperidol versus chlorpromazine for schizophrenia","author":"Leucht","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD011810.pub2-BIB0041|cit41","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007778","article-title":"Chlorpromazine dose for people with schizophrenia","author":"Liu","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011810.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1192\/bjp.176.3.249","article-title":"Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia","volume":"176","author":"Marshall","year":"2000","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD011810.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1038\/mp.2012.47","article-title":"Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents","volume":"17","author":"Miyamoto","year":"2012","journal-title":"Molecular Psychiatry"},{"key":"10.1002\/14651858.CD011810.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1001\/jama.285.15.1987","article-title":"The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials","volume":"285","author":"Moher","year":"2001","journal-title":"JAMA"},{"issue":"7","key":"10.1002\/14651858.CD011810.pub2-BIB0045|cit45","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed1000097","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Medicine"},{"key":"10.1002\/14651858.CD011810.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/00002826-198906000-00002","article-title":"Which atypical antipsychotics are identified by screening tests?","volume":"12","author":"Moore","year":"1989","journal-title":"Clinical Neuropharmacology"},{"key":"10.1002\/14651858.CD011810.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The brief psychiatric rating scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological Reports"},{"key":"10.1002\/14651858.CD011810.pub2-BIB0048|cit48","first-page":"273","article-title":"A review of the adverse side effects associated with antipsychotics as related to their efficacy","volume":"26 Suppl 1","author":"Pakpoor","year":"2014","journal-title":"Psychiatria Danubina"},{"issue":"1","key":"10.1002\/14651858.CD011810.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1001\/archpsyc.64.1.19","article-title":"Lifetime prevalence of psychotic and bipolar I disorders in a general population","volume":"64","author":"Perala","year":"2007","journal-title":"Archives of General Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD011810.pub2-BIB0050|cit50","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010631","article-title":"Chlorpromazine versus atypical antipsychotic drugs for schizophrenia","author":"Saha","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011810.pub2-BIB0051|cit51","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JPT Deeks JJ Glasziou P Chapter 12: Interpreting results and drawing conclusions. In Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD011810.pub2-BIB0052|cit52","unstructured":"Sterne JAC Egger M Moher D (editors) Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention . Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"5","key":"10.1002\/14651858.CD011810.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta3050","article-title":"Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review","volume":"3","author":"Ukoumunne","year":"1999","journal-title":"Health Technology Assessment"},{"issue":"7","key":"10.1002\/14651858.CD011810.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1192\/pb.bp.108.021949","article-title":"Loss to outcomes stakeholder survey: the LOSS study","volume":"33","author":"Xia","year":"2009","journal-title":"Psychiatric Bulletin"},{"issue":"5","key":"10.1002\/14651858.CD011810.pub2-BIB0055|cit55","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011655","article-title":"Chlorpromazine versus metiapine for schizophrenia","author":"Zare","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011810.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/BF01277947","article-title":"Clozapine and other neuroleptic drugs antagonize the light-evoked suppression of melatonin biosynthesis in chick retina: involvement of the D4-like dopamine receptor","volume":"97","author":"Zawilska","year":"1994","journal-title":"Neural Transmission"},{"issue":"8","key":"10.1002\/14651858.CD011810.pub2-BIB0057|cit57","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011810","article-title":"Chlorpromazine versus clotiapine for schizophrenia","author":"Mazhari","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD011810.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T02:17:11Z","timestamp":1709173031000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD011810.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Schizophrenia Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2017,4,7]]},"references-count":57,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2017,4]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd011810.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,7]]}}}